{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:48:13Z","timestamp":1793911693406,"version":"4.8.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","award":["CRC-2023-00155"],"award-info":[{"award-number":["CRC-2023-00155"]}],"id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-56756-3","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T21:00:53Z","timestamp":1742936453000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Performance of plasma biomarkers for diagnosis and prediction of dementia in a Brazilian cohort"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0694-733X","authenticated-orcid":false,"given":"Luis E.","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Mattos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thais L.","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananssa","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Drummond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4738-1368","authenticated-orcid":false,"given":"Felipe Kenji","family":"Sudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1663-8346","authenticated-orcid":false,"given":"Fernanda","family":"Barros-Arag\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Vanderborght","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Ot\u00e1vio","family":"Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio T.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"IDOR Memory Clinic Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0292-5985","authenticated-orcid":false,"given":"Fernanda","family":"Tovar-Moll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8358-0589","authenticated-orcid":false,"given":"Fernanda G.","family":"De Felice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"56756_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jalz.2012.11.007","volume":"9","author":"M Prince","year":"2013","unstructured":"Prince, M. et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer\u2019s. Dement 9, 63 (2013).","journal-title":"Alzheimer\u2019s. Dement"},{"key":"56756_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3389\/fnagi.2016.00253","volume":"8","author":"S Baez","year":"2016","unstructured":"Baez, S. & Ib\u00e1\u00f1ez, A. Dementia in Latin America: an emergent silent tsunami. Front Aging Neurosci. 8, 253 (2016).","journal-title":"Front Aging Neurosci."},{"key":"56756_CR3","unstructured":"IBGE. Censo Demogr\u00e1fico 2022. https:\/\/agenciadenoticias.ibge.gov.br\/agencia-noticias\/2012-agencia-de-noticias\/noticias\/38186-censo-2022-numero-de-pessoas-com-65-anos-ou-mais-de-idade-cresceu-57-4-em-12-anos (2023)."},{"key":"56756_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"56756_CR5","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","volume":"18","author":"TK Karikari","year":"2022","unstructured":"Karikari, T. K. et al. Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat. Rev. Neurol. 18, 400\u2013418 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"56756_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13195-019-0485-0","volume":"11","author":"O Hansson","year":"2019","unstructured":"Hansson, O., Lehmann, S., Otto, M., Zetterberg, H. & Lewczuk, P. Advantages and disadvantages of the use of the CSF Amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer\u2019s Disease. Alzheimers Res Ther. 11, 34 (2019).","journal-title":"Alzheimers Res Ther."},{"key":"56756_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40336-015-0102-6","volume":"3","author":"O Sabri","year":"2015","unstructured":"Sabri, O., Seibyl, J., Rowe, C. & Barthel, H. Beta-amyloid imaging with florbetaben. Clin. Transl. Imaging 3, 13\u201326 (2015).","journal-title":"Clin. Transl. Imaging"},{"key":"56756_CR8","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1001\/jamaneurol.2017.2814","volume":"74","author":"S Janelidze","year":"2017","unstructured":"Janelidze, S. et al. Concordance between different amyloid immunoassays and visual amyloid positron emission tomographic assessment. JAMA Neurol. 74, 1492\u20131501 (2017).","journal-title":"JAMA Neurol."},{"key":"56756_CR9","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2023","unstructured":"Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146, 1592\u20131601 (2023).","journal-title":"Brain"},{"key":"56756_CR10","doi-asserted-by":"crossref","unstructured":"Hunter, T. R., Santos, L. E., Tovar-Moll, F., & De Felice, F. G. Alzheimer\u2019s disease biomarkers and their current use in clinical research and practice. Mol. Psychiatry 30, 272\u2013284 (2025).","DOI":"10.1038\/s41380-024-02709-z"},{"key":"56756_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 21, 66\u201377 (2022).","journal-title":"Lancet Neurol."},{"key":"56756_CR12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13195-023-01314-6","volume":"15","author":"B Dubois","year":"2023","unstructured":"Dubois, B., von Arnim, C. A. F., Burnie, N., Bozeat, S. & Cummings, J. Biomarkers in Alzheimer\u2019s disease: role in early and differential diagnosis and recognition of atypical variants. Alzheimers Res Ther. 15, 175 (2023).","journal-title":"Alzheimers Res Ther."},{"key":"56756_CR13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772\u2013781 (2020).","journal-title":"JAMA"},{"key":"56756_CR14","unstructured":"Jack C. et al. Revised Criteria for Diagnosis and Staging of Alzheimer\u2019s Disease: Alzheimer\u2019s Association Workgroup (2023)."},{"key":"56756_CR15","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1093\/gerona\/glad025","volume":"78","author":"L Bertola","year":"2023","unstructured":"Bertola, L. et al. Prevalence of dementia and cognitive impairment no dementia in a large and diverse nationally representative sample: the ELSI-Brazil Study. J. Gerontol. Ser. A 78, 1060\u20131068 (2023).","journal-title":"J. Gerontol. Ser. A"},{"key":"56756_CR16","doi-asserted-by":"publisher","first-page":"e180021","DOI":"10.1590\/1980-549720180021.supl.1","volume":"21","author":"DC Malta","year":"2018","unstructured":"Malta, D. C. et al. Preval\u00eancia da hipertens\u00e3o arterial segundo diferentes crit\u00e9rios diagn\u00f3sticos, Pesquisa Nacional de Sa\u00fade. Rev. Bras. Epidemiol. 21, e180021 (2018).","journal-title":"Rev. Bras. Epidemiol."},{"key":"56756_CR17","doi-asserted-by":"publisher","unstructured":"Francisco, PMSB. et al. Diabetes mellitus in older adults, prevalence and incidence: results of the FIBRA study. Rev Bras Geriatr e Gerontol 25, https:\/\/doi.org\/10.1590\/1981-22562022025.210203.en (2022).","DOI":"10.1590\/1981-22562022025.210203.en"},{"key":"56756_CR18","doi-asserted-by":"publisher","unstructured":"Lotufo, P. A. et al. Self-reported high-cholesterol prevalence in the brazilian population: analysis of the 2013 national health survey. Arq. Bras. Cardiol. https:\/\/doi.org\/10.5935\/abc.20170055 (2017).","DOI":"10.5935\/abc.20170055"},{"key":"56756_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze, S. et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat. Med. 26, 379\u2013386 (2020).","journal-title":"Nat. Med"},{"key":"56756_CR20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen, E. H. et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat. Med. 26, 387\u2013397 (2020).","journal-title":"Nat. Med."},{"key":"56756_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13195-023-01319-1","volume":"15","author":"F Mart\u00ednez-Dubarbie","year":"2023","unstructured":"Mart\u00ednez-Dubarbie, F. et al. Accuracy of plasma A\u03b240, A\u03b242, and p-tau181 to detect CSF Alzheimer\u2019s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform. Alzheimers Res Ther. 15, 163 (2023).","journal-title":"Alzheimers Res Ther."},{"key":"56756_CR22","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202217123","volume":"15","author":"G Salvad\u00f3","year":"2023","unstructured":"Salvad\u00f3, G. et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol. Med 15, e17123 (2023).","journal-title":"EMBO Mol. Med"},{"key":"56756_CR23","doi-asserted-by":"publisher","unstructured":"Ashton, N. J. et al. Diagnostic accuracy of a plasma phosphorylated Tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2023.5319 (2024).","DOI":"10.1001\/jamaneurol.2023.5319"},{"key":"56756_CR24","first-page":"1797","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0, M. et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat. Med. 28, 1797\u20131801 (2022).","journal-title":"Nat. Med"},{"key":"56756_CR25","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton, N. J. et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 141, 709\u2013724 (2021).","journal-title":"Acta Neuropathol."},{"key":"56756_CR26","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3233\/JAD-215646","volume":"87","author":"A Pilotto","year":"2022","unstructured":"Pilotto, A. et al. Differences between plasma and cerebrospinal fluid p-tau181 and p-tau231 in early Alzheimer\u2019s disease. J. Alzheimer\u2019s. Dis. 87, 991\u2013997 (2022).","journal-title":"J. Alzheimer\u2019s. Dis."},{"key":"56756_CR27","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler, S. E. et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology 93, e1647\u2013e1659 (2019).","journal-title":"Neurology"},{"key":"56756_CR28","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/alz.12801","volume":"19","author":"C Rabe","year":"2023","unstructured":"Rabe, C. et al. Clinical performance and robustness evaluation of plasma amyloid\u2010\u03b2 42\/40 prescreening. Alzheimer\u2019s. Dement 19, 1393\u20131402 (2023).","journal-title":"Alzheimer\u2019s. Dement"},{"key":"56756_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13195-021-00942-0","volume":"14","author":"AL Benedet","year":"2022","unstructured":"Benedet, A. L. et al. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimers Res. Ther. 14, 26 (2022).","journal-title":"Alzheimers Res. Ther."},{"key":"56756_CR30","doi-asserted-by":"publisher","first-page":"470","DOI":"10.2174\/156720510791383796","volume":"7","author":"PE Spies","year":"2010","unstructured":"Spies, P. E. et al. The cerebrospinal fluid amyloid \u03b242\/40 ratio in the differentiation of Alzheimer\u2019s disease from non-Alzheimer\u2019s dementia. Curr. Alzheimer Res 7, 470\u2013476 (2010).","journal-title":"Curr. Alzheimer Res"},{"key":"56756_CR31","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/acn3.274","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze, S. et al. CSF A\u03b242\/A\u03b240 and A\u03b242\/A\u03b238 ratios: better diagnostic markers of Alzheimer disease. Ann. Clin. Transl. Neurol. 3, 154\u2013165 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"56756_CR32","doi-asserted-by":"publisher","first-page":"e238214","DOI":"10.1001\/jamanetworkopen.2023.8214","volume":"6","author":"LS Honig","year":"2023","unstructured":"Honig, L. S. et al. Evaluation of plasma biomarkers for A\/T\/N classification of Alzheimer disease among adults of caribbean hispanic ethnicity. JAMA Netw. Open 6, e238214 (2023).","journal-title":"JAMA Netw. Open"},{"key":"56756_CR33","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/alz.12332","volume":"17","author":"JR Chong","year":"2021","unstructured":"Chong, J. R. et al. Plasma P\u2010tau181 to A\u03b242 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer\u2019s disease patients with concomitant cerebrovascular disease. Alzheimer\u2019s. Dement 17, 1649\u20131662 (2021).","journal-title":"Alzheimer\u2019s. Dement"},{"key":"56756_CR34","doi-asserted-by":"crossref","unstructured":"Fowler, C. J. et al. Plasma p\u2010tau181\/A\u03b21\u201042 ratio predicts A\u03b2\u2010PET status and correlates with CSF\u2010p\u2010tau181\/A\u03b21\u201042 and future cognitive decline. Alzheimer\u2019s Dement Diagnosis, Assess. Dis. Monit. 14, e12375 (2022).","DOI":"10.1002\/dad2.12375"},{"key":"56756_CR35","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","volume":"28","author":"MM Mielke","year":"2022","unstructured":"Mielke, M. M. et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat. Med. 28, 1398\u20131405 (2022).","journal-title":"Nat. Med"},{"key":"56756_CR36","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","volume":"19","author":"A Pichet Binette","year":"2023","unstructured":"Pichet Binette, A. et al. Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimer\u2019s. Dement 19, 1403\u20131414 (2023).","journal-title":"Alzheimer\u2019s. Dement"},{"key":"56756_CR37","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/S1474-4422(18)30231-X","volume":"17","author":"JJ Bazarian","year":"2018","unstructured":"Bazarian, J. J. et al. Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study. Lancet Neurol. 17, 782\u2013789 (2018).","journal-title":"Lancet Neurol."},{"key":"56756_CR38","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41582-021-00616-3","volume":"18","author":"A Abdelhak","year":"2022","unstructured":"Abdelhak, A. et al. Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nat. Rev. Neurol. 18, 158\u2013172 (2022).","journal-title":"Nat. Rev. Neurol."},{"key":"56756_CR39","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1136\/jnnp-2024-333467","volume":"95","author":"S Lehmann","year":"2024","unstructured":"Lehmann, S. et al. Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment. J. Neurol. Neurosurg. Psychiatry 95, 1046\u20131053 (2024).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"56756_CR40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1001\/jamaneurol.2021.4222","volume":"79","author":"MC Gonzalez","year":"2022","unstructured":"Gonzalez, M. C. et al. Association of Plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia with Lewy bodies. JAMA Neurol. 79, 32 (2022).","journal-title":"JAMA Neurol"},{"key":"56756_CR41","doi-asserted-by":"crossref","unstructured":"Planche, V. et al. Validity and performance of blood biomarkers for alzheimer disease to predict dementia risk in a large clinic-based cohort. Neurology 100, e473\u2013e484 (2022).","DOI":"10.1212\/WNL.0000000000201479"},{"key":"56756_CR42","doi-asserted-by":"publisher","unstructured":"Cecchetti, G. et al. Diagnostic accuracy of automated Lumipulse plasma pTau-217 in Alzheimer\u2019s disease. https:\/\/doi.org\/10.1101\/2024.05.20.24307613 (2024).","DOI":"10.1101\/2024.05.20.24307613"},{"key":"56756_CR43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13195-024-01513-9","volume":"16","author":"J Arranz","year":"2024","unstructured":"Arranz, J. et al. Diagnostic performance of plasma pTau217, pTau181, A\u03b21\u201042 and A\u03b21\u201040 in the LUMIPULSE automated platform for the detection of Alzheimer disease. Alzheimers Res Ther. 16, 139 (2024).","journal-title":"Alzheimers Res Ther."},{"key":"56756_CR44","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze, S. et al. Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer Disease. JAMA Neurol. 78, 1375\u20131382 (2021).","journal-title":"JAMA Neurol."},{"key":"56756_CR45","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet, A. L. et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 78, 1471 (2021).","journal-title":"JAMA Neurol."},{"key":"56756_CR46","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1002\/alz.12806","volume":"18","author":"J Simr\u00e9n","year":"2022","unstructured":"Simr\u00e9n, J. et al. Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability. Alzheimer\u2019s. Dement 18, 1988\u20131992 (2022).","journal-title":"Alzheimer\u2019s. Dement"},{"key":"56756_CR47","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/s41591-023-02380-x","volume":"29","author":"B Bellaver","year":"2023","unstructured":"Bellaver, B. et al. Astrocyte reactivity influences amyloid-\u03b2 effects on tau pathology in preclinical Alzheimer\u2019s disease. Nat. Med. 29, 1775\u20131781 (2023).","journal-title":"Nat. Med."},{"key":"56756_CR48","doi-asserted-by":"publisher","first-page":"9188","DOI":"10.18632\/aging.102391","volume":"11","author":"C Drummond","year":"2019","unstructured":"Drummond, C. et al. Narrative impairment, white matter damage and CSF biomarkers in the Alzheimer\u2019s disease spectrum. Aging (Albany NY) 11, 9188\u20139208 (2019).","journal-title":"Aging (Albany NY)"},{"key":"56756_CR49","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2796.2004.01380.x","volume":"256","author":"B Winblad","year":"2004","unstructured":"Winblad, B. et al. Mild cognitive impairment \u2013 beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J. Intern Med. 256, 240\u2013246 (2004).","journal-title":"J. Intern Med"},{"key":"56756_CR50","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (American Psychiatric Association, 2013).","DOI":"10.1176\/appi.books.9780890425596"},{"key":"56756_CR51","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/alz.12510","volume":"18","author":"IMW Verberk","year":"2022","unstructured":"Verberk, I. M. W. et al. Characterization of pre\u2010analytical sample handling effects on a panel of Alzheimer\u2019s disease\u2013related blood\u2010based biomarkers: results from the standardization of Alzheimer\u2019s blood biomarkers (SABB) working group. Alzheimer\u2019s. Dement 18, 1484\u20131497 (2022).","journal-title":"Alzheimer\u2019s. Dement"},{"key":"56756_CR52","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker, L. A. et al. New creatinine- and cystatin C\u2013based equations to estimate GFR without race. N. Engl. J. Med. 385, 1737\u20131749 (2021).","journal-title":"N. Engl. J. Med"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56756-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56756-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56756-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T12:57:20Z","timestamp":1743253040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56756-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["56756"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-56756-3","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"22 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2911"}}